It was just surprising to me these patents were mentioned because I read here that Teva's request to amend its complaint to include these patents was denied by the Court. I would be even more surprised if they have been discussed to support or refute an indefiniteness argument in an earlier patent because they are only related to the characterization of Copaxone by patented markers. Surely Momenta could use other markers or methods.
News 
Market Data 
Discover 
AI
